Effects of Clinical Pharmacist-Led Medication Management on Medication Adherence and Quality of Life in Stroke Patients Undergoing Intravenous Thrombolysis.

The intervention group had significantly lower LDL-C levels at 1 month compared to the control group.

• LDL-C at 1 month: 2.11 (1.64–2.53) mmol/L in the intervention group vs 2.33 (1.80–2.96) mmol/L in the control group.
• Difference was statistically significant (P=0.037).
• Study included 190 patients total (93 control, 97 intervention).
• Data were collected retrospectively from a prospective stroke database between January and October 2023.

The intervention group showed a greater reduction in LDL-C from baseline at 1 month compared to the control group.

• LDL-C reduction from baseline: 0.98 (0.38–1.46) mmol/L in the intervention group vs 0.70 (0.22–1.31) mmol/L in the control group.
• Difference was statistically significant (P=0.044).
• Multivariate analysis confirmed the pharmacist-led intervention as an independent predictor of greater LDL-C reduction (β=0.239 mmol/L; P=0.016).

Pharmacist-led medication management was independently associated with optimal medication adherence at 3 months.

• Medication adherence at 3 months was higher in the intervention group compared to the control group.
• The pharmacist-led intervention was independently associated with optimal adherence (adjusted OR, 3.03; 95% CI, 1.53–5.99; P=0.001).
• Adherence was assessed at 3-month follow-up.

Functional outcomes at 3 months did not differ significantly between the intervention and control groups.

• No statistically significant differences in functional outcomes were observed between the two groups at 3 months.
• Baseline characteristics, including statin use and length of hospital stay, were comparable between groups.

The study population consisted of acute ischemic stroke patients receiving intravenous thrombolysis assigned to pharmacist-led intervention or standard care.

• 190 patients were included: 93 in the control group and 97 in the intervention group.
• Data were collected from a prospective stroke database between January and October 2023 and analyzed retrospectively.
• Outcomes assessed included 1-month lipid profiles and LDL-C reduction, and 3-month medication adherence and clinical outcomes.